Wed, Mar 26, 4:10 PM, Zacks
ARIAD Candidate in Phase II Study - Analyst Blog
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
Wed, Mar 5, 9:58 AM, Zacks
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.